COVID19: a variabilidade individual da resposta imunoinflamatória

Autores

DOI:

https://doi.org/10.11606/issn.2176-7262.rmrp.2022.180873

Palavras-chave:

COVID-19, Síndrome respiratória aguda grave, Resposta imunoinflamatória, Modelo iceberg de doença, Resultado do tratamento

Resumo

A diversidade das respostas imunoinflamatórias individuais humanas muito provavelmente tem papel na gravidade da doença Covid19 causada pela infecção pelo vírus SARS-CoV2. Marcadores imunológicos séricos durante a Covid19 podem guiar a escolha de terapias individualizadas com melhores resultados. O tratamento eficiente para Covid19 pode exigir: 1) detecção precoce da doença, 2) terapia medicamentosa combinada com alvo ao 3) ciclo de replicação do vírus e 4) terapia anti-inflamatória individualizada para perfis de respostas imunoinflamatórias humanas, administradas em tempo hábil. É improvável que a Covid19 seja a última doença humana emergente com potencial de alastramento veloz pandêmico. Reunir conhecimento sobre perfis de respostas imunoinflamatórias individuais dos hospedeiros humanos é uma oportunidade ímpar que pode nos levar a entender as diferenças dessas respostas entre indivíduos, abrindo caminho para estratégias terapêuticas mais rápidas e eficientes no combate à futuras epidemias.

Downloads

Os dados de download ainda não estão disponíveis.

Biografia do Autor

  • Maria Goreti Rosa-Freitas, Geniac | Fiocruz (aposentada)

    PhD in Molecular Biology

  • Carolina Muruci-Cruz, Independent Medical Doctor, Rio de Janeiro,(RJ), Brazil

    MD-Doctor of Medicine & BSc Biology

     

  • Luiz Fernando Dale, Clínica Dale, Rio de Janeiro, (RJ), Brazil

    MD-Doctor of Medicine, CEO and specialist in Human Fertilization at Clínica Dale & Researcher at FIOCRUZ (in leave of absence)

     

  • Luis Eduardo da Cruz, Axis Biotec Brazil, Rio de Janeiro, (R)J, Brazil
      BSc Pharmacy, former CEO and current Consultant at Axis Biotec

     

  • Jorge Kalil, Universidade de São Paulo, São Paulo, (SP), Brazil
      PhD, Full Professor  and Head of Clinical Immunology and Allergy at USP; former Director Butantan Institute

Referências

United Nations [homepage on the Internet]. Geneva: Department of Economic and Social Affairs. Population Dynamics.; c2020 [cited 2020 August 7]. Available from https://population.un.org/wpp/Download/Standard/Population/

Last JM. The iceberg "completing the clinical picture" in general practice. The Lancet 1963; 282 (7297): 28–31.

Martinez, EZ et al. Prevalence of virological and serological markers of SARS-CoV-2 infection in the population of Ribeirão Preto, Southeast Brazil: an epidemiological survey. Revista da Sociedade Brasileira de Medicina Tropical [online]. 2021, v. 54 [Accessed 17 November 2021] , e0210-2021. Epub 02 July 2021. ISSN 1678-9849. https://doi.org/10.1590/0037-8682-0210-2021.

Casanova JL. Human genetic basis of interindividual variability in the course of infection. Proc Natl Acad Sci USA. 2015;112(51):E7118–E7127.

Coronavirus Resource Center [homepage on the Internet]. Baltimore: Johns Hopkins University; c2020 [cited 2020 September 22]. Available from https://coronavirus.jhu.edu/map.html

Covid19-coronavirus-infographic-datapack [homepage on the Internet]. London: Information is beautiful; c2020 [cited 2020 August 29]. Available from https://informationisbeautiful.net/visualizations/Covid19-coronavirus-infographic-datapack/

Population by country [homepage on the Internet]. Delaware: Worldometers info; c2020 [cited 2020 August 29]. Available from https://www.worldometers.info/world-population/population-by-country/

EPICOVID-19 [homepage on the Internet]. Pelotas: University of Pelotas; c2020 [cited 2020 June 11]. Available from http://epidemio-ufpel.org.br/uploads/downloads/19c528cc30e4e5a90d9f71e56f8808ec.pdf.

Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of Covid19: immunity, inflammation and intervention [published online ahead of print, 2020 Apr 28]. Nat Rev Immunol. 2020;1–12.

Merad M, Martin JC. Pathological inflammation in patients with Covid19: a key role for monocytes and macrophages. Nat Rev Immunol 2020;20,355–362.

Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with Covid19 in China: a nationwide analysis [published online ahead of print March 26, 2020]. Eur Respir J. 2020; https://doi.org/10.1183/13993003.00547-2020.

Li X, Xu S, Yu M, Yu M, Wang K, Tao Y, et al. Risk factors for severity and mortality in adult Covid19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110–118. doi:10.1016/j.jaci.2020.04.006

Wu C, Chen X, Cai Y, Xia, Zhou X, Xu S, et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–943.

Debnath M, Banerjee M, Berk M. Genetic gateways to COVID‐19 infection: Implications for risk, severity, and outcomes. The FASEB Journal. 2020;34:8787–8795.

Ferrara JL, Abhyankar S, Gilliland DG. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. Transplant Proc. 1993; 25(1 Pt 2):1216–7.

Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012; 76(1):16–32.

Sierra B, Perez AB, Vogt K, Garcia G, Schmolke K, Aguirre E, et al. Secondary heterologous dengue infection risk: Disequilibrium between immune regulation and inflammation? Cellular Immunology. 2010; 262 (2): 134–140.

Penha-Gonçalves C. Genetics of Malaria Inflammatory Responses: A Pathogenesis Perspective. Front Immunol. 2019;10:1771.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395:497–506.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223):507–513.

Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerging Microbes & Infections. 2020;9:761–770.

Polak SB, Van Gool IC, Cohen D, Thüsen JH, Paassen J. A systematic review of pathological findings in Covid19: a pathophysiological timeline and possible mechanisms of disease progression. Modern Pathol. 2020;33:2128–2138.

Zhou F, Ting Yu, Ronghui Du, Guohui Fan, Ying Liu, Zhibo Liu, et al. Clinical course and risk factors for mortality of adult inpatients with Covid19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395:1054–62.

Downloads

Publicado

2022-07-04 — Atualizado em 2022-07-06

Edição

Seção

Ensaio

Como Citar

1.
Rosa-Freitas MG, Muruci-Cruz C, Dale LF, Cruz LE da, Kalil J. COVID19: a variabilidade individual da resposta imunoinflamatória. Medicina (Ribeirão Preto) [Internet]. 6º de julho de 2022 [citado 24º de abril de 2024];55(2):e-180873. Disponível em: https://www.revistas.usp.br/rmrp/article/view/180873